2024-05-03 11:30:00 ET
Summary
- Crispr Therapeutics AG stock has plunged deep into a bear market.
- The FOMO attributed to Crispr's Casgevy approvals is likely dissipated.
- Crispr has an expanding early-stage portfolio. Crispr is also gaining traction to improve Casgevy's safety profile.
- Crispr Therapeutics stock is also no longer overvalued, as late buyers likely rushed out quickly.
- The stock's selling intensify has also slowed, allowing dip-buyers an attractive opportunity to load up.
I upgraded CRISPR Therapeutics AG ( CRSP ) stock to a Hold rating in late February 2024 after anticipating that the worst seemed over for CRSP . As a reminder, I cautioned investors about chasing after CRSP's surging optimism in late November 2023 as the market assessed the potentially historic approval for Casgevy then....
Read the full article on Seeking Alpha
For further details see:
Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)